Pharming Group (PHAR) Price & Analysis

Compare

191 Followers

PHAR Stock Chart & Stats

$16.04

>-$0.01(-0.06%)

At close: Jan 14 4:00 PM EST

$16.04

>-$0.01(-0.06%)

Day’s Range― - ―

52-Week Range$7.50 - $21.34

Previous CloseN/A

Volume11.43K

Average Volume (3M)30.80K

Market Cap

$1.18B

Enterprise Value$1.15B

Total Cash (Recent Filing)$141.54M

Total Debt (Recent Filing)$111.52M

Price to Earnings (P/E)1113.9

Beta0.45

Next Earnings

Mar 12, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.10

Shares Outstanding70,140,400

10 Day Avg. Volume42,770

30 Day Avg. Volume30,805

Financial Highlights & Ratios

PEG Ratio-3.28

Price to Book (P/B)3.03

Price to Sales (P/S)2.26

P/FCF Ratio-258.67

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue3.17

Enterprise Value/Gross Profit3.52

Enterprise Value/Ebitda25.64

Forecast

1Y Price Target

$39.50

Price Target Upside146.26% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Adult Market ResilienceSustained growth in adult APDS sales provides a reliable revenue stream that can offset delays in pediatric commercialization.

Commercial PerformanceStrong commercial traction of lead products and continued uptake of Joenja supports a durable revenue base that can sustain growth even if pediatric approval is delayed.

R&D InvestmentElevated operating spending to bolster late-stage clinical programs signals commitment to advancing the pipeline and could increase the chance of valuable future approvals.

Bears Say

Pediatric Dosing UncertaintyFDA-flagged potential underexposure in lower-weight pediatric patients indicates further pharmacokinetic studies may be required, which could necessitate dose adjustments and delay access for some children.

Regulatory SetbackThe FDA's Complete Response Letter for the pediatric supplemental application, citing additional pediatric pharmacokinetic and exposure data and an analytical manufacturing testing issue, represents a regulatory setback that could delay pediatric approval.

Revenue Guidance RiskExcluding pediatric contributions from guidance because of uncertainty increases downside risk to revenue forecasts if the pediatric development pathway remains unresolved.

Pharming Group News

Morning Movers: Disney dips following fourth quarter earnings

Stock futures are weaker in pre-market action, pressured by a dramatic reversal in precious metals, triggering broader selling...

5d ago

DIS

DVN

Pharming to host virtual investor day

Virtual Investor Day to be held on February 3 at 10 am. ...

5d ago

PHAR

Pharming receives CRL from U.S. FDA for sNDA for Joenja

Pharming (PHAR) Group announced that the U.S. Food and Drug Administration, FDA, has issued a Complete Response Letter,...

5d ago

PHAR

FDA Calendar: These Are the Remaining Drug Approvals Anticipated This Month

Since the start of the month, the U.S. Food and Drug Administration (FDA) has made its decision on...

8d ago

AQST

IRON

Pharming Group Sets 2026 Guidance and Showcases Rare Disease Pipeline at Investor Day

Pharming Group ( ($PHAR) ) has issued an update. On February 3, 2026, Pharming Group issued 2026 financial...

4d ago

PHAR

Pharming Group Beats 2025 Revenue Guidance and Sets February Investor Day

Pharming Group ( ($PHAR) ) has issued an announcement. On January 8, 2026, Pharming Group reported preliminary, unaudited...

30d ago

PHAR

Pharming price target raised to $42 from $41 at Oppenheimer

Oppenheimer raised the firm’s price target on Pharming (PHAR) to $42 from $41 and keeps an Outperform rating...

3M ago

PHAR

Pharming Group Reports Strong Q3 2025 Growth

Pharming Group Nv ( ($PHAR) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

PHAR

Pharming Group Reports Strong Q3 2025 Financial Growth and Strategic Updates

Pharming Group ( ($PHAR) ) just unveiled an announcement. Pharming Group reported significant financial growth in the third...

3M ago

PHAR

Pharming Group to Present New Data at ACAAI 2025

Pharming Group ( ($PHAR) ) just unveiled an update. On October 20, 2025, Pharming Group announced that 12...

4M ago

PHAR

Pharming Group Announces Restructuring to Cut Costs and Boost Growth

An announcement from Pharming Group ( ($PHAR) ) is now available. On October 6, 2025, Pharming Group announced...

4M ago

PHAR

Pharming announces 20% net reduction in non-commercial, non-medical headcount

Pharming (PHAR) Group announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is...

4M ago

PHAR

Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group and keeping the price target...

4M ago

PHAR

Pharming Group’s Leniolisib Receives FDA Priority Review for Pediatric APDS Treatment

Pharming Group ( ($PHAR) ) has shared an update. On October 1, 2025, Pharming Group announced that the...

4M ago

PHAR

PHAR FAQ

What was Pharming Group’s price range in the past 12 months?

Pharming Group lowest stock price was $7.50 and its highest was $21.34 in the past 12 months.

What is Pharming Group’s market cap?

Pharming Group’s market cap is $1.18B.

When is Pharming Group’s upcoming earnings report date?

Pharming Group’s upcoming earnings report date is Mar 12, 2026 which is in 33 days.

How were Pharming Group’s earnings last quarter?

Pharming Group released its earnings results on Nov 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.004 by $0.096.

Is Pharming Group overvalued?

According to Wall Street analysts Pharming Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharming Group pay dividends?

Pharming Group does not currently pay dividends.

What is Pharming Group’s EPS estimate?

Pharming Group’s EPS estimate is 0.02.

How many shares outstanding does Pharming Group have?

Pharming Group has 70,140,400 shares outstanding.

What happened to Pharming Group’s price movement after its last earnings report?

Pharming Group reported an EPS of $0.1 in its last earnings report, beating expectations of $0.004. Following the earnings report the stock price went up 11.533%.

Which hedge fund is a major shareholder of Pharming Group?

Currently, no hedge funds are holding shares in PHAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharming Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

0.44%

Trailing 12-Months

Asset Growth

11.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Pharming Group (PHAR) Earnings & Revenues

Historic Earnings Reports

PHAR Company Deck

PHAR Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong financial performance with significant revenue growth and an optimistic future outlook. The primary growth drivers, RUCONEST and Joenja, have performed exceptionally well, and the upgraded revenue guidance underscores company confidence. However, challenges exist with the international market withdrawal of RUCONEST and the VUS reclassification timeline. Overall, the positive aspects outweigh the challenges.View all PHAR earnings summaries

PHAR Stock 12 Month Forecast

Average Price Target

$39.50

▲(146.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","43":"$43","15.25":"$15.25","24.5":"$24.5","33.75":"$33.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.25,24.5,33.75,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.975,18.900000000000002,20.825000000000003,22.75,24.675,26.6,28.525,30.45,32.375,34.3,36.225,38.15,40.075,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.975,18.70769230769231,20.440384615384616,22.173076923076923,23.90576923076923,25.63846153846154,27.371153846153845,29.103846153846156,30.83653846153846,32.56923076923077,34.301923076923075,36.034615384615385,37.767307692307696,{"y":39.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.975,18.515384615384615,20.055769230769233,21.596153846153847,23.136538461538464,24.676923076923078,26.217307692307692,27.75769230769231,29.298076923076923,30.838461538461537,32.378846153846155,33.919230769230765,35.45961538461538,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.065,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.623,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.235,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.67,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 61, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.975,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >